Oncolytics Biotech appointed Steve Glover, former Ambrx chairman, to its board of directors and promoted John McAdory to Chief Operating Officer to oversee clinical operations and business development. The moves signal organizational strengthening as the company advances pelareorep immunotherapy programs toward registration-enabling studies.